ArriVent BioPharma, Inc. (AVBP)Healthcare | Biotechnology | Newtown Square, United States | NasdaqGM
33.64 USD
-0.05
(-0.148%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 33.64 |
Hot Take ↕ | July 11, 2026, 5:01 a.m. EDT
ArriVent BioPharma presents a classic biotech dilemma: a pristine balance sheet masking a lack of profitability. The company holds a fortress-like cash position with negligible debt, allowing it to weather the storm while waiting for its EGFR Firmonertinib trials to deliver results. However, the stock is currently trading at a premium to its book value despite generating negative free cash flow and negative returns on equity, a valuation gap that demands a catalyst to close. While the analyst consensus is overwhelmingly bullish, the price action tells a different story; the stock has failed to sustain the momentum seen earlier in the year and is now consolidating near its 50-day average. The options market reflects this uncertainty, with heavy put buying at current levels acting as a circuit breaker against further declines. Until the clinical trial data provides definitive proof of efficacy, the investment case remains speculative, relying entirely on the eventual success of the pipeline rather than current operational performance. |
| Model | MAE |
|---|---|
| MSTL_123 ✓ | 0.088712 |
| MSTL | 0.098891 |
| AutoTheta | 0.105370 |
| AutoARIMA | 0.105554 |
| AutoETS | 0.105556 |
Forecast horizon: 60 days | Selected: MSTL_123
| Forecast Reliability | |
|---|---|
| Score | 39% |
| H-stat | 5.24 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.495 |
| Excess Kurtosis | -0.51 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.129 |
| Market Cap | 1,566,780,544 |
| Forward P/E | -9.61 |
| Beta | 1.30 |
| Website | https://arrivent.com |
As of July 11, 2026, 5:01 a.m. EDT: Speculators are positioning for volatility rather than a clear directional bet. Call Open Interest is heavily concentrated at strikes significantly below the current price (deep ITM), suggesting a hedge against downside or a belief in a floor around $22-$25. Conversely, Put volume shows aggressive new flow into ATM and OTM strikes ($35, $40) with volume exceeding open interest, indicating active hedging or speculation on a potential drop. The imbalance in volume suggests traders are buying protection or betting on a decline more actively than they are initiating leveraged upside plays at these specific expirations.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5404664 |
| Address1 | 18 Campus Boulevard |
| Address2 | Suite 100 |
| All Time High | 36.37 |
| All Time Low | 14.35 |
| Ask | 41.85 |
| Ask Size | 2 |
| Audit Risk | 5 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 651,010 |
| Average Daily Volume3 Month | 550,270 |
| Average Volume | 550,270 |
| Average Volume10Days | 651,010 |
| Beta | 1.299 |
| Bid | 24.08 |
| Bid Size | 2 |
| Board Risk | 9 |
| Book Value | 7.15 |
| City | Newtown Square |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 33.64 |
| Current Ratio | 13.951 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 33.93 |
| Day Low | 32.362 |
| Debt To Equity | 0.129 |
| Display Name | ArriVent BioPharma |
| Earnings Timestamp | 1,778,529,600 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 1,240,819,584 |
| Eps Current Year | -4.02411 |
| Eps Forward | -3.49943 |
| Eps Trailing Twelve Months | -3.38 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 30.6627 |
| Fifty Day Average Change | 2.9772987 |
| Fifty Day Average Change Percent | 0.09709839 |
| Fifty Two Week Change Percent | 54.046642 |
| Fifty Two Week High | 35.83 |
| Fifty Two Week High Change | -2.1900024 |
| Fifty Two Week High Change Percent | -0.06112203 |
| Fifty Two Week Low | 16.1 |
| Fifty Two Week Low Change | 17.539999 |
| Fifty Two Week Low Change Percent | 1.089441 |
| Fifty Two Week Range | 16.1 - 35.83 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,706,279,400,000 |
| Float Shares | 29,777,214 |
| Forward Eps | -3.49943 |
| Forward P E | -9.612994 |
| Free Cashflow | -82,842,624 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 77 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.016339999 |
| Held Percent Institutions | 0.96005994 |
| Implied Shares Outstanding | 46,574,928 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,024-01-26 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania. |
| Long Name | ArriVent BioPharma, Inc. |
| Market | us_market |
| Market Cap | 1,566,780,544 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1671738162 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -145,240,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,569,109,324 |
| Number Of Analyst Opinions | 11 |
| Open | 33.24 |
| Operating Cashflow | -134,472,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 628 277 4836 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 33.64 |
| Post Market Time | 1,783,981,118 |
| Previous Close | 33.69 |
| Price Eps Current Year | -8.359612 |
| Price Hint | 2 |
| Price To Book | 4.704895 |
| Profit Margins | 0.0 |
| Quick Ratio | 13.058 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0499992 |
| Regular Market Change Percent | -0.14841 |
| Regular Market Day High | 33.93 |
| Regular Market Day Low | 32.362 |
| Regular Market Day Range | 32.362 - 33.93 |
| Regular Market Open | 33.24 |
| Regular Market Previous Close | 33.69 |
| Regular Market Price | 33.64 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 322,357 |
| Return On Assets | -0.34719002 |
| Return On Equity | -0.5517 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 46,574,928 |
| Shares Percent Shares Out | 0.16370001 |
| Shares Short | 7,624,281 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 7,709,676 |
| Short Name | ArriVent BioPharma, Inc. |
| Short Percent Of Float | 0.1743 |
| Short Ratio | 10.56 |
| Source Interval | 15 |
| State | PA |
| Symbol | AVBP |
| Target High Price | 50.0 |
| Target Low Price | 34.0 |
| Target Mean Price | 43.63636 |
| Target Median Price | 45.0 |
| Total Cash | 326,380,000 |
| Total Cash Per Share | 7.008 |
| Total Debt | 419,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.38 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 24.4316 |
| Two Hundred Day Average Change | 9.208399 |
| Two Hundred Day Average Change Percent | 0.37690526 |
| Type Disp | Equity |
| Volume | 322,357 |
| Website | https://arrivent.com |
| Zip | 19,073 |